Добірка наукової літератури з теми "Fraude pharmaceutique"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Зміст
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Fraude pharmaceutique".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Дисертації з теми "Fraude pharmaceutique"
Nzalakanda, Rufin. "La performativité de la grande entreprise pharmaceutique dans la chaîne de développement des produits de santé : une analyse de la fraude fondée sur le concept de Poche organisationnelle Informelle (P.O.I)." Electronic Thesis or Diss., Paris, HESAM, 2021. https://tel.archives-ouvertes.fr/tel-04164360.
Повний текст джерелаSince the 1950s, the pharmaceutical industry is still affected by the scandals of health scandals (thalidomide 1961, 1962 and 1963), Distilbène (1977), Vioxx (2004), Mediator (2009), breast prostheses PIP (2010), ...These are generally health products that have a harmful effect that is not detected earlier in the collective management of these products throughout the health product development chain. These harmful effects have generated disastrous consequences in France and abroad ( some organizations say that these are cases of pain that have caused illness, cancer or death), but also in economic and financial terms (national health costs), image and trust. This is the diagnosis made about the functioning of the pharmaceutical industry. This diagnosis reveals the existence of a dilemma that this sector must undoubtedly resolve. Various situations are often mentioned to refer to this dilemma. Some situations refer to the negligence and imprudence of institutions and organizations for the control and supervision of health products, others are oriented towards the fault and error of the actors involved in the collective management of these products, and others are about fraud perpetrated by actors mandated to develop health products that help the population to eliminate the different diseases. This thesis focuses on situations of fraud committed by big pharma as a research subject. She positions him in the field of white-collar crime, a term invented by American sociologist Edwin. Sutheland in the 1930s). The analysis of this research subject poses a practical question: How big pharma performs to normalize fraud in the health product development chain that includes national, transnational and global levels. It is important to note that this thesis does not aim to stigmatize big pharma, which are essential actors because they contribute to the disappearance of diseases by providing health products to society. Rather, it focuses on a phenomenon that has been clearly identified and that represents a threat to the planet, which has already affected health systems several times, thousands of people in the world and caused considerable human and financial losses. Thus, it relies on the experience of institutional, organizational and individual actors in the health sector, in terms of health scandals marked by pharmaceutical fraud, to answer research questions. The research results show that, big pharma is instrumentalising P.O.I, a structured and structuring organisation, to perform the actors who are involved in the collective management of health products in such a way that their practices and discourse are consistent with what she thinks, says and does. It is through this mechanism that pharmaceutical fraud is normalized at the national, transnational and global levels. More specifically, the P.O.I is a network organisation composed of human and non-human actors.Hidden within the big pharma, it materializes the ability of this enterprise to produce a generalized effect in the process that describes the different phases of realization of a health product, which will encourage the actors involved to legitimize the fraud in order to serve the interests of the entreprise in which it is housed
Raclot, Jean. "La marque pharmaceutique." Lyon 3, 1990. http://www.theses.fr/1990LYO33016.
Повний текст джерелаThe subject of this thesis is to present the specificity of the pharmaceutical trademark. In a long introduction the author brings the pharmaceutical trademark and the differents means to designate a patent medicine and the difference between the notions of patent medicines ans the common denominations (dc). At the end of this introduction the author exibit the historical evolution of pharmaceutical tradmark right and the functions and utility of these. This thesis includes two parts: the choise and the protection of the pharmaceutical trademark. In the first part the author brings the variety of signe that it is possible to choose by way of pharmaceutical trademark (nominative or emblematics trademarks) then the lawful conditions of thise, the notions of independance of pharmaceutical trademark in comparaison with the patent medicine and the person and finally the distinctivity of pharmaceutical trademark. In the second part the author brings the protection of the pharma cautical trademark against the imitations and the generics medicines
Delenta, Christophe. "L'export dans l'industrie pharmaceutique en France." Paris 5, 1999. http://www.theses.fr/1999PA05P070.
Повний текст джерелаMoreno, Pontier Annick. "Les produits pharmaceutiques génériques." Montpellier 1, 1993. http://www.theses.fr/1993MON10023.
Повний текст джерелаLaboulbenne, Sophie. "Application aux enregistrements internationaux d'un logiciel de gestion administrative des spécialités pharmaceutiques en France." Bordeaux 2, 1994. http://www.theses.fr/1994BOR2P044.
Повний текст джерелаNobili, Anne. "La qualification du personnel de l'officine pharmaceutique." Aix-Marseille 3, 1998. http://www.theses.fr/1998AIX32036.
Повний текст джерелаIn exchange for a drug retail distribution monopoly, which is consented to them in the interest of public health, chemists are subjected to many obligations. In particular, these obligations consist of qualifications requirements for people working in chemists' shops. They concern, first of all, chemists whose long and high level university education is a guarantee of competence and the quality of the pharmaceutical act (part i). They also apply to other members of the chemist's staff. Only certificied assistants can carry out preparation and distribution operations, under the chemist's supervision (part ii). This is the principle of "personal exercise" which required the chemist, when he doesn't carry out these operations himself, to carefully supervise them. Then, in virtue of this principle, a chemist must be present in the chemist's shop to ensure that a member of a medical profession is always available (part iii)
Lamaison, Ludovic. "Le bilan de l'industrie pharmaceutique en 1992." Bordeaux 2, 1993. http://www.theses.fr/1993BOR2P103.
Повний текст джерелаMouhssine, Najat. "L'exercice illégal de la pharmacie et le monopole pharmaceutique." Bordeaux 1, 1988. http://www.theses.fr/1988BOR1D008.
Повний текст джерелаLEGALLY, "NO ONE IS ALLOWED TO PRATISE PHARMACY IF HE DOES NOT FULFIL THE RIQUIRED CONDITIONS FOR THIS PURPOSE" ARTICLE L. 514 OF THE "PUBLIC HEALTH" CODE. WHOEVER INFRINGES THIS CLAUSE COMMITS THE INDICTABLE OFFENCE OF ILLEGAL PRACTISE OF PHARMACY, AN OFFENCE ANTICIPTED AND PENALIZED BY THE L. 517 ARTICLE OF THE "PUBLIC HEALTH" CODE. NOW, WE HAVE BEEN NOTICING SINCE A CERTAIN TIME A CONSIDERABLE DEVELOPMENT OF THE ACTIVITY OF CERTAIN IMPORTANT DISTRIBUTORS WHO, IN ORDER TO "SMACK" WHAT THEY REGARD AS UNLAWFUL RESTRICTIONS TO COMPETITION, "TACKLE" NOT ONLY THE PARA-PHARMACY MARKET - OF WHICH THE EXCLUSIVE RIGHTS CONSTITUTED, ACCOR- DING TO THEM, A COMPETITIVE PRACTISE INTOLERABLE AND ILLICIT - BUT ALSO AND PARTICULARY THE MARKET OF MEDECINE BY COMMERCIALIZING PRODUCTS without ANY NOTICE ON THEIR PACKING, AS THOUGH NOT ALLEGING THERAPEUTIC PROPERTIES TO THE PRODUCT WAS SUFFICIENT TO RENDER IT A NON-MEDICINAL PRODUCT, THEREFORE A HARMLESS PRODUCT FOR CURRENT CONSUMPTION. THESE NEW FORMS OF DISTRIBUTION HAVE RESTARTED THE DEBATE ON WHAT BE- LONGS TO THE PHARMACY BY RIGHT AND WHAT SHOULD BE SOLD FREELY without ANY HARM FOR THE PUBLIC HEALTH. AT THE INTERSECTING POINT OF THESE QUERIES, IS TO BE
Harreguy, Annabelle. "L'externalisation de la distribution pharmaceutique en France : les prestataires logistiques." Bordeaux 2, 2000. http://www.theses.fr/2000BOR2P018.
Повний текст джерелаCharbit, Albert. "La création du "guide des formations complémentaires aux études pharmaceutiques" et analyse des diplômes ouverts aux pharmaciens." Paris 5, 1995. http://www.theses.fr/1995PA05P241.
Повний текст джерелаКниги з теми "Fraude pharmaceutique"
Ruffat, Michèle. 175 ans d'industrie pharmaceutique française: Histoire de Synthélabo. Paris: La Découverte, 1996.
Знайти повний текст джерелаExperiment Eleven: Dark secrets behind the discovery of a wonder drug. New York, N.Y: Walker & Co., 2012.
Знайти повний текст джерелаBlondeau, Alexandre. Histoire des laboratoires pharmaceutiques en France et de leurs médicaments: Des préparations artisanales aux molécules du XXIe siècle. Paris: Le Cherche midi, 1992.
Знайти повний текст джерелаLe Marche De L'emballage Pharmaceutique En France (Pharmaceutical Packaging). MSI Marketing Research for Industry Ltd, 2001.
Знайти повний текст джерелаVidal de la famille: Le dictionnaire des médicaments. [Issy-les-Moulineaux]: Vidal, 2005.
Знайти повний текст джерелаBlondeau, Alexandre. Histoire des laboratoires pharmaceutiques en France et de leurs médicaments, tome 3. Le Cherche-midi Editeur, 1999.
Знайти повний текст джерелаBlondeau, Alexandre. Histoire des laboratoires pharmaceutiques en France et de leurs médicaments, tome 2. Le Cherche-midi Editeur, 1994.
Знайти повний текст джерелаLtd, ICON Group. ILE DE FRANCE PHARMACEUTIQUE: International Competitive Benchmarks and Financial Gap Analysis (Financial Performance Series). 2nd ed. Icon Group International, Inc., 2000.
Знайти повний текст джерелаSociété Universelle de la Croix-Blanc and Société Des Experts-Chimistes de Fran. Annales des Falsifications: Bulletin International de la Répression des Fraudes Alimentaires & Pharmaceutiques, Volumes 1-2... Creative Media Partners, LLC, 2018.
Знайти повний текст джерелаSociété Universelle de la Croix-Blanc and Société Des Experts-Chimistes de Fran. Annales des Falsifications: Bulletin International de la Répression des Fraudes Alimentaires & Pharmaceutiques, Volumes 1-2... Creative Media Partners, LLC, 2019.
Знайти повний текст джерелаЧастини книг з теми "Fraude pharmaceutique"
de Pouvourville, Gérard, Pierre-Louis Bras, and Didier Tabuteau. "45. L'industrie pharmaceutique en France." In Traité d'économie et de gestion de la santé, 415–26. Presses de Sciences Po, 2009. http://dx.doi.org/10.3917/scpo.bras.2009.01.415.
Повний текст джерела